摘要
非小细胞肺癌(NSCLC)脑转移的患者预后较差,酪氨酸酶抑制剂(TKI)显著改善了表皮生长因子受体(EGFR)基因敏感突变患者的预后。EGFR敏感突变与NSCLC的脑转移发生率相关并可能影响其放疗和药物治疗疗效,脑转移瘤的EGFR-TKI单药治疗和放疗均有效,二者联合是否较单一治疗改善EGFR基因突变的NSCLC脑转移患者的预后。回顾性研究提示先行放疗,尤其是立体定向放射外科联合治疗可能更具优势,但存在争议。因此,对EGFR基因突变NSCLC的脑转移放疗相关临床研究进展进行综述。
The prognosis of patients with brain metastases from non-small cell lung cancer(NSCLC)is poor.Tyrosine kinase inhibitor(TKI)significantly improves the prognosis of patients with epidermal growth factor receptor(EGFR)sensitive mutation.EGFR sensitive mutations are associated with the incidence of brain metastases in NSCLC and may affect the efficacy of radiotherapy and TKI therapy.Both EGFR-TKI and radiotherapy are effective for EGFR-mutant NSCLC with brain metastases.Whether the combination of EGFR-TKI and radiotherapy may improve the prognosis compared with EGFR-TKI or radiotherapy alone has been studied.Retrospective studies have indicated that upfront radiotherapy,especially upfront stereotaxic radiosurgery combined with EGFR-TKI may be more advantageous in improving the prognosis,but it is still controversial.Therefore,clinical research progresses on the radiotherapy for EGFR-mutant NSCLC patients with brain metastases were reviewed.
作者
向星
杨文刚
陈霞霞
耿一超
马筑
苏胜发
欧阳伟炜
卢冰
Xiang Xing;Yang Wengang;Chen Xiaxia;Geng Yichao;Ma Zhu;Su Shengfa;Ouyang Weiwei;Lu Bing(Department of Oncology,Clinical College of Guizhou Medical University,Affiliated Hospital of Guizhou Medical University/Guizhou Provincial Cancer Hospital,Guiyang 550004,China)
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2021年第6期637-642,共6页
Chinese Journal of Radiation Oncology
基金
贵州省科技支撑计划(黔科合支撑(2019)2795号)。
关键词
脑转移
非小细胞肺癌/综合疗法
表皮生长因子受体
酪氨酸酶抑制剂
放射疗法
Brain metastasis,non-small-cell lung carcinoma/comprehensive treatment
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Radiotherapy
